Literature DB >> 746498

Potassium studies in chronic obstructive airways disease.

W S Watson, R Hume, G R Sutherland.   

Abstract

Seventeen male patients with chronic obstructive airways disease in remission were separated into two groups according to arterial carbon dioxide tensions. Hypercapnia was associated significantly with hypoxia and increased red cell volume whereas normocapnia was not. Normocapnic patients were significantly lighter than those with hypercapnia. Total body potassium (TBK) measured by the whole body monitor was significantly low in two of the patients studied (P less than 0.005). The mean value for TBK for the normocapnic group as a whole was significantly low (P less than 0.005), but the mean value for the hypercapnic group was not. Serum potassium and erythrocyte potassium concentrations were normal even when TBK was low, and diuretics had no apparent influence on these potassium values. Of four patients (two in the series and two others) who had TBK measured after a recent episode of cor pulmonale, three had significantly low values. The only previous studies using a whole body monitor to measure TBK in chronic obstructive airways disease found no such low values, though other workers estimating exchangeable potassium by isotope dilution techniques had found evidence of gross potassium depletion. It is concluded that low TBK does indeed occur in patients with chronic obstructive airways disease and that gross depletion is more likely to follow an episode of cor pulmonale.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 746498      PMCID: PMC470971          DOI: 10.1136/thx.33.6.734

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  16 in total

1.  Distribution of sodium and potassium in chronic obstructive pulmonary disease.

Authors:  N Telfer; J M Weiner; Q Merrill
Journal:  Am Rev Respir Dis       Date:  1975-02

2.  Total body potassium in cor pulmonale.

Authors:  A D Howie; A I Pack; K Boddy; M Mahaffey
Journal:  Thorax       Date:  1976-12       Impact factor: 9.139

3.  ACTUAL AND PREDICTED-NORMAL RED-CELL AND PLASMA VOLUMES IN PRIMARY AND SECONDARY POLYCYTHAEMIA.

Authors:  R HUME; A GOLDBERG
Journal:  Clin Sci       Date:  1964-06       Impact factor: 6.124

4.  Total body exchangeable potassium and sodium and extracellular fluid in chronic pulmonary insufficiency.

Authors:  G L BAUM; M M DICK; A BLUM; A KAUPE; J CARBALLO
Journal:  Am Heart J       Date:  1959-07       Impact factor: 4.749

5.  Potassium depletion in patients with chronic respiratory failure.

Authors:  P R Schloerb; C R King; G Kerby; W E Ruth
Journal:  Am Rev Respir Dis       Date:  1970-07

6.  Energy provision, tissue utilization, and weight loss in prolonged starvation.

Authors:  J Runcie; T E Hilditch
Journal:  Br Med J       Date:  1974-05-18

7.  The relation of total body potassium to height, weight, and age in normal adults.

Authors:  K Boddy; P C King; R Hume; E Weyers
Journal:  J Clin Pathol       Date:  1972-06       Impact factor: 3.411

8.  Oxygen therapy in chronic respiratory failure.

Authors:  R Hume; P J Rooney; D L McLellan
Journal:  Br Med J       Date:  1973-10-20

9.  Total body and exchangeable potassium in chronic airways obstruction: a controversial area?

Authors:  K Boddy; D L Davies; A D Howie; M M Madkour; M E Mahaffy; A I Pack
Journal:  Thorax       Date:  1978-02       Impact factor: 9.139

10.  Total body potassium in long-term frusemide therapy: is potassium supplementation necessary?

Authors:  H J Dargie; K Boddy; A C Kennedy; P C King; P R Read; D M Ward
Journal:  Br Med J       Date:  1974-11-09
View more
  2 in total

1.  Diet, absorption, and hormone studies in relation to body weight in obstructive airways disease.

Authors:  P d'A Semple; W S Watson; G H Beastall; M I Bethel; J K Grant; R Hume
Journal:  Thorax       Date:  1979-12       Impact factor: 9.139

2.  Endocrine and metabolic studies in unstable cor pulmonale.

Authors:  P D Semple; W S Watson; G H Beastall; R Hume
Journal:  Thorax       Date:  1983-01       Impact factor: 9.139

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.